| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.102.3.272 |
| P698 | PubMed publication ID | 10899087 |
| P50 | author | Steven E. Reis | Q47700105 |
| P2093 | author name string | A M Feldman | |
| B H Lorell | |||
| S E Reis | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metastatic breast cancer | Q12859063 |
| trastuzumab | Q412616 | ||
| P304 | page(s) | 272-274 | |
| P577 | publication date | 2000-07-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity | |
| P478 | volume | 102 |
| Q47323865 | Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). |
| Q80510573 | Biology and therapy of malignant solid tumors in childhood |
| Q35817552 | Building better monoclonal antibody-based therapeutics. |
| Q47149101 | Cardiac Nonmyocyte Cell Functions and Crosstalks in Response to Cardiotoxic Drugs |
| Q35035923 | Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity |
| Q36117002 | Cardiac sympathetic hyperactivity after chemotherapy: early sign of cardiotoxicity? |
| Q77129319 | Cardiomyopathy caused by antineoplastic therapies |
| Q33574045 | Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention |
| Q38104812 | Cardiovascular safety and hemodynamic considerations in oncology drug development – webinar highlights October 10th 2012 |
| Q74268516 | Combinations for cancer prevention |
| Q45205623 | Does spironolactone ameliorate trastuzumab-induced cardiac toxicity? |
| Q77632286 | Down regulation of B cells by immunization with a fusion protein of a self CD20 peptide and a foreign IgG.Fc fragment |
| Q51367703 | Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy |
| Q47124548 | Effects of neuregulin-1 on autonomic nervous system remodeling post-myocardial infarction in a rat model |
| Q34545577 | ErbB signaling in cardiac development and disease |
| Q34279655 | HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity |
| Q46440272 | Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure |
| Q28188254 | Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo |
| Q36663524 | Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy |
| Q28829301 | Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition |
| Q34102834 | Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? |
| Q38166071 | Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury |
| Q35020538 | Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy |
| Q84247687 | Neuregulin in heart failure : reverse translation from cancer cardiotoxicity to new heart failure therapy |
| Q38829737 | Oncocardiology-Past, Present, and Future: A Review |
| Q73839673 | Pharmacoepidemiology and drug safety |
| Q36637796 | Pharmacogenomics as a Risk Mitigation Strategy for Chemotherapeutic Cardiotoxicity |
| Q42911854 | Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents |
| Q36891697 | Role of anthracyclines in the era of targeted therapy |
| Q38784568 | Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy |
| Q36294169 | The Experience of a Multidisciplinary Clinic in the Management of Early-Stage Breast Cancer Patients Receiving Trastuzumab Therapy: An Observational Study |
| Q36916630 | The emerging role of pharmacogenomics in biologics |
| Q28512555 | The transcription factor GATA-6 regulates pathological cardiac hypertrophy |
| Q26799470 | Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening |
| Q33800955 | Trastuzumab Administration in Patients with Metastatic Breast Cancer - Experience of a Large University Breast Center |
| Q37378906 | Trastuzumab and doxorubicin-related cardiotoxicity and the cardioprotective role of exercise |
| Q47572376 | Trastuzumab therapy and the heart: palliation at what cost? |
| Q33840140 | Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population |
| Q38686222 | Update on cardiotoxicity of anti-cancer treatments |
| Q39332072 | Valvular Heart Disease in Cancer Patients: Etiology, Diagnosis, and Management |
| Q47286758 | Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity. |
| Q57649939 | α-Tocopheryloxyacetic acid is superior to α-tocopheryl succinate in suppressing HER2-high breast carcinomas due to its higher stability |
Search more.